29.6 C
Thursday, May 23, 2024

Bayer invests €400 million for new production facilities for contraceptives

- Advertisement -

Firm promotes benefits of fewer cases of maternal deaths, unwanted pregnancies

Bayer recently announced an investment of over €400 million in new production facilities for long-acting reversible contraceptives.

It includes the construction of a new production site in Alajuela, Costa Rica, and the expansion of production capabilities in Turku, Finland.

Benefits of contraception—Less cases (76%) of maternal death, unwanted pregnancies (64%), child mortality (76%).

In 2019, Bayer pledged to provide 100 million women in low-and-middle-income countries with access to family planning by 2030.

For more than 50 years, Bayer has supported educational programs and rights-based family planning in more than 130 countries, particularly by increasing access to modern forms of contraception.

This initiative is part of Bayer’s comprehensive set of sustainability measures and commitments and is in line with the United Nations Sustainable Development Goals (UN SDGs).

“We believe every girl and woman deserves the chance to determine her own future. That’s why Bayer is partnering with local and international organizations, such as the United Nations Population Fund and the United States Agency for International Development, to empower women to make informed decisions about family planning,” said Mildred Nadah Pita, Head of Global Healthcare Programs/Sustainability Middle Africa at Bayer.

“With Bayer’s commitment to provide 100 million women in low- and middle-income countries with access to modern contraception by 2030, we are making an important contribution to achieving the UN Sustainable Development Goals by improving the health, rights and economic status of women around the world, which is a fundamental prerequisite for greater equality, education, and prosperity for all.”

Shaping women’s health from menarche to menopause

While pursuing research to find new treatment options for gynecological diseases with a high unmet medical need, Bayer is also working on addressing women’s health needs during menopause.

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause.

“Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally. With increased longevity, maintaining the functional ability and good quality of life is extremely relevant from both a healthcare and a socio-economic perspective. Unfortunately, menopause remains a taboo topic, leaving many women untreated,” said Cecilia Caetano, MD, Head of Medical Affairs Menopause at Bayer.

“With our strong heritage and deeply rooted expertise in women’s health, we continue to focus on providing innovative science, solutions, and education to support the individual health need of women.”


Popular Articles